Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 388 citing articles:

Therapeutic Targeting of the Tumor Microenvironment
Leire Bejarano, Marta Joana Costa Jordão, Johanna A. Joyce
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 933-959
Open Access | Times Cited: 1062
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
Nayoung Kim, Hong Kwan Kim, Kyungjong Lee, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 869
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl, Michael Untch, Nicole Burchardi, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1279-1288
Open Access | Times Cited: 565
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Candice R. Gurbatri, Ioana Lia, Rosa L. Vincent, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 530
Open Access | Times Cited: 412
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Yilun Wu, Weiyu Chen, Zhi Ping Xu, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 354
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Hao Zhang, Ziyu Dai, Wantao Wu, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 347
Emerging new therapeutic antibody derivatives for cancer treatment
Shijie Jin, Yanping Sun, Liang Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 319
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 273
Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses
Qian Chen, Muchao Chen, Zhuang Liu
Chemical Society Reviews (2019) Vol. 48, Iss. 22, pp. 5506-5526
Closed Access | Times Cited: 254
Immunotherapy of Melanoma: Facts and Hopes
Sarah A. Weiss, Jedd D. Wolchok, Mario Sznol
Clinical Cancer Research (2019) Vol. 25, Iss. 17, pp. 5191-5201
Open Access | Times Cited: 236
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto, Francheska Caminero, Lindsay Cash, et al.
Translational Oncology (2020) Vol. 13, Iss. 3, pp. 100738-100738
Open Access | Times Cited: 234
Clinical development of targeted and immune based anti-cancer therapies
Nicole A. Seebacher, Alexandra E. Stacy, Georgia Porter, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 207
Immune checkpoints in the tumor microenvironment
Salman M. Toor, Varun Sasidharan Nair, Julie Decock, et al.
Seminars in Cancer Biology (2019) Vol. 65, pp. 1-12
Closed Access | Times Cited: 196
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
Wenjuan Liu, Yue Du, Ru Wen, et al.
Pharmacology & Therapeutics (2019) Vol. 206, pp. 107438-107438
Closed Access | Times Cited: 170
Necroptosis in Immuno-Oncology and Cancer Immunotherapy
Jenny Sprooten, Pieter De Wijngaert, Isaure Vanmeerbeek, et al.
Cells (2020) Vol. 9, Iss. 8, pp. 1823-1823
Open Access | Times Cited: 146
Prevotellaceae produces butyrate to alleviate PD-1/PD-L1 inhibitor-related cardiotoxicity via PPARα-CYP4X1 axis in colonic macrophages
Yaxin Chen, Yanzhuo Liu, Yang Wang, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 134
Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy
Shuang Liang, Jianjun Yao, Dan Liu, et al.
Advanced Materials (2023) Vol. 35, Iss. 33
Closed Access | Times Cited: 123
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 2, pp. e003776-e003776
Open Access | Times Cited: 121
Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses
Joyce Wei, Welby Montalvo-Ortiz, Lola Yu, et al.
Science Immunology (2021) Vol. 6, Iss. 58
Open Access | Times Cited: 108
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
Antonio Galvano, Valerio Gristina, Umberto Malapelle, et al.
ESMO Open (2021) Vol. 6, Iss. 3, pp. 100124-100124
Open Access | Times Cited: 104
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Charu Aggarwal, Amy Prawira, Scott Antonia, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e004424-e004424
Open Access | Times Cited: 96
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue
Zhi Li, Zewen Kelvin Tuong, Isaac Dean, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 6
Open Access | Times Cited: 76
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
Qiaofei Liu, Jiayi Li, Huaijin Zheng, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 66
Single-cell and spatial transcriptomics analysis of non-small cell lung cancer
Marco De Zuani, Haoliang Xue, Jun Sung Park, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 35
Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy
Ryungsa Kim, Takanori Kin, William T. Beck
Cancers (2024) Vol. 16, Iss. 5, pp. 984-984
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top